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Abstract  We  report  a  neonatal  case  of  systemic  pseudohypoaldosteronism  type  1  caused  by
a novel  mutation  in  the  SCNN1A  gene  (homozygous  c.1052  + 2dupT  in  intron  3)  in  which  the
patient presented  with  life-threatening  hyperkalemia,  hyponatremia  and  metabolic  acidosis.  It
remains uncertain  if  there  is  genotype--phenotype  correlation,  due  to  the  rarity  of  the  disease.
This mutation,  which  to  our  best  knowledge  has  not  been  described  before,  was  associated  with
a very  severe  phenotype  requiring  aggressive  therapy.









Un  caso  de  pseudohipoaldosteronismo  sistémico  con  una  mutación  nueva  en  el  gen
SCNN1A
Resumen  Se  presenta  un  caso  neonatal  de  pseudohipoaldosteronismo  sistémico  tipo  1  causado
por una  nueva  mutación  en  el  gen  SCNN1A  (homocigotos  C.1052  2  dupT  en  el  intrón  3)  en  el  que
el se  evidenció  hiperpotasemia  potencialmente  mortal,  hiponatremia  y  acidosis  metabólica.
Continúa sin  saberse  con  certeza  si  hay  correlación  genotipo-fenotipo,  debido  a  la  rareza  de
la enfermedad.  Esta  mutación,  que  no  ha  sido  previamente  descrita,  se  asoció  con  un  fenotipo
muy grave  por  lo  que  requirió  un  abordaje  terapéutico  agresivo.
© 2012  SEEN.  Publicado  por  Elsevier  España,  S.L.  Todos  los  derechos  reservados.
∗ Corresponding author.
E-mail address: nicolemad@gmail.com (N. Silva).
Introduction
Hyponatremia  and  hyperkalemia  can  represent  a variety  of
renal  and  genetic  disorders  with  significant  long-term  health
implications.2
Pseudohypoaldosteronism  type  1  (PHA  1)  is  a rare  genetic
aldosterone  unresponsiveness  syndrome.5 The  diagnosis  is
1575-0922/$ – see front matter © 2012 SEEN. Published by Elsevier España, S.L. All rights reserved.
http://dx.doi.org/10.1016/j.endonu.2012.07.002
2173-5093/$ – see front matter © 2012 SEEN. Published by Elsevier España, S.L. All rights reserved.
Endocrinol Nutr. 2013;60(1):33–36
34 N. Silva et al.
established  by  the  presence  of  high  levels  of  serum  aldos-
terone  and  plasma  renin  activity  associated  with  clinical
and  laboratory  findings  of  hypoaldosteronism.9 There  are
two  forms  that  are  clinically  and  genetically  distinct.  Sys-
temic  PHA  1  has  an  autosomal  recessive  transmission  and
result  from  mutations  in  the  genes  encoding  the  epithe-
lial  sodium  channel  (ENaC)  that  exists  in  multiple  organs.
Affected  patients  typically  have  a  severe  phenotype  and
require  extremely  high  doses  of  sodium,  indefinitely,  to  com-
pensate  their  severe  multiorgan  salt  wasting.2 Renal  PHA  1
has  an  autosomal  dominant  transmission  and  results  from
mutations  in  the  gene  that  encodes  the  mineralocorticoid
receptor  (MR)  that  exists  predominantly  on  the  kidney.  Gen-
erally,  as  the  mineralocorticoid  resistance  is  isolated  to  this
organ,  patients  have  a  mild  phenotype  which  often  improves
spontaneously  after  a  variable  period  of  time.2
Herein  we  report  a  10-day-old  male  newborn,  who  devel-
oped  severe  hyperkalemia,  hyponatremia  and  metabolic
acidosis,  initially  diagnosed  as  congenital  adrenal  hyper-
plasia  (CAH)  based  on  an  initial  high  level  of  17-
hydroxyprogesterone.  Endocrinological  study  subsequently
revealed  high  levels  of  renin  and  aldosterone,  which  led
to  the  diagnosis  of  PHA  1.  It  was  the  severity  of  his  clini-
cal  course  and  his  systemic  manifestations  that  made  the
clinical  diagnosis  of  systemic  PHA  1,  leading  to  screening
of  ENaC  mutations  which  found  a  homozygous  mutation  in
intron  3  of  the  SCNN1A  gene  (c.1052  +  2dupT),  which  to  our
best  knowledge  has  never  been  described  before.
Case report
A  10-day-old  male  newborn  was  admitted  to  our  hospi-
tal  due  to  two  episodes  of  vomiting  and  dehydration.
He  was  born  at  full  term  with  a  birth  weight  of  3010  g
(10--25th  percentile)  and  there  were  no  perinatal  prob-
lems.  There  was  no  history  of  parental  consanguinity.  His
older  sibling,  a  6-year-old  female,  had  been  diagnosed  with
Chediak--Higashi  syndrome.  Upon  admission  he  looked  sick,
‘‘septic’’  and  dehydrated  with  a  capillary  refill  time  of
3  s.  Heart  auscultation  revealed  arrhythmic  heart  sounds,
sometimes  associated  with  bradycardia.  He  had  no  evidence
of  hyperpigmentation  and  other  physical  examination  find-
ings  were  unremarkable.  Blood  pressure  was  89/59  mmHg,
median  arterial  pressure  (MAP)  76  mmHg  (50--90th  centile),
heart  rate  varied  between  60  and  120/min,  respiratory  rate
was  40/min,  oxygen  saturation  was  80%  in  room  air  and
body  temperature  was  36.5 ◦C.  Blood  glucose  was  normal.
Additionally,  his  weight  was  2715  g  (weight  loss  of  9.8%).
Electrocardiogram  at  admission  in  Intensive  Care  Unit
was  compatible  with  ventricular  tachycardia  and  ini-
tial  laboratory  evaluation  revealed  the  following:  sodium
125  mEq/L;  potassium  >10  mEq/L;  chloride  104  mEq/L;
urea  62  mg/dL;  creatinine  0.2  mg/dL;  C-reactive  protein
<2.9  g/dL;  hemoglobin  21.5  g/dL  and  hematocrit  58%.  The
venous  blood  gas  analysis  showed  a  mild  metabolic  acid-
osis  (pH  7.28,  PCO2 48.9  mmHg,  HCO3 22.6  mmol/L,  BE
−4  mEq/L).  Initial  17-hydroxyprogesterone  level  was  slightly
raised  (10.76  ng/mL)  and  the  rest  of  the  endocrinologic
study  was  in  progress.  He  received  normal  saline  to  correct
dehydration  and  calcium  gluconate,  sodium  bicarbonate,
nebulized  salbutamol,  glucose  insulin  infusion  and  ion
exchange  resin  to  control  hyperkalemia.  Intravenous  hydro-
cortisone  (30  mg/kg/day)  was  started  as  CAH  was  initially
suspected.  Despite  these  measures,  he  did  not  improve
clinically  and  hyponatremia  did  not  correct  with  large
amounts  of  fluid  and  sodium  intake.  Attempts  at  taper-
ing  treatment  of  hyperkalemia  resulted  in  recurrence  of
severe  hyperkalemia.  Thus,  higher  doses  of  intravenous
hydrocortisone  (maximum:  200  mg/kg/day)  and  oral  fludro-
cortisone  (1.5  mg/day)  were  administered.  Determination
of  17-hydroxyprogesterone  on  Guthrie  card  and  molecular
study  of  CYP  21A2  were  performed  and  were  normal.
The  endocrinological  study  obtained  at  the  time  of  pre-
sentation  subsequently  revealed  normal  levels  of  serum
cortisol,  ACTH,  17-hydroxyprogesterone  and  DHEA  sul-
fate  but  markedly  elevated  levels  of  serum  aldosterone
(1750  ng/dL:  range  7--184  ng/dL)  and  plasma  renin  activ-
ity  (70  ng/ml/h;  range  0.4--1.9  ng/ml/h),  hence  a  diagnosis
of  pseudohypoaldosteronism  was  made  and  steroids  were
tapered.  Hyponatremia  and  dehydration  continued  severely
in  spite  of  large  fluid  and  sodium  intake  and  sodium  balance
was  only  achieved  with  35  mEq/kg/day  of  sodium  chloride.
Glucose  and  insulin  infusion,  calcium  gluconate,  sodium
bicarbonate  and  nebulized  salbutamol  were  tapered  and
stopped  and  potassium  controlled  with  high  dose  of  ion
exchange  resin.  During  hospitalization,  he  was  noted  to  have
episodes  of  sweating  and  also  recurrent  episodes  of  tachyp-
nea  and  fever  mimicking  respiratory  infections.
He  was  discharged  home  with  5.5  months  on  oral  20%
saline  (30  mEq/kg/day)  and  ion  exchange  resin  (6  times
a  day).  Since  then  he  has  had  recurrences  of  fluid  and
electrolyte  imbalances  necessitating  repeated  short-term
hospitalizations.
The  study  of  the  SCNN1B,  SCNN1G  and  SCNN1A  was  car-
ried  out  subsequently  and  a  homozygous  mutation  in  intron  3
of  the  SCNN1A  gene  was  detected  (c.1052  +  2dupT)  (Fig.  1).
The  patient  is  currently  8.5  months  old  and  his  growth,
in  weight  and  length,  is  below  the  third  percentile.  He  also
has  a  mild  development  delay  and  is  under  a  stimulation
program  achieving  some  improvements.
Discussion
Our  patient  presented  with  hyponatremic  dehydration,
metabolic  acidosis  and  severe  hyperkalemia.  CAH  is  the
most  frequent  cause  of  severe  dehydration,  hyponatremia
and  hyperkalemia  in  the  newborn  period,  and  therefore  this
was  our  first  diagnosis,  supported  by  a initial  high  level
of  17-hydroxyprogesterone.  However,  such  severe  hyper-
kalemia,  that  almost  leads  to  cardiac  arrest,  is  unusual  in
hyponatremic  dehydration  without  hemolysis,  renal  failure
or  significant  intake  of  potassium.2 Also,  the  disappointing
response  to  increasing  doses  of  steroids  made  CAH  a less
likely  diagnosis.  17-hydroxyprogesterone  may  be  falsely  high
in  sick  newborns;  therefore  a  repeated  assessment  may  be
required  for  the  diagnosis.  This  could  explain  our  initial  high
level  of  17-hydroxyprogesterone.  PHA  1  can  be  differen-
tiated  clinically  from  CAH  by  an  earlier  onset  and  by  no
response  to  steroid  therapy,  given  the  delay  in  obtaining
results  for  many  hormonal  assays.10
PHA  1  was  first  described  in  1958  by  Cheek  and  Perry4.
Since  then,  various  case  reports  have  been  published  and
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Figure  1  Electrophoretogram  of  the  exon  3--intron  3  transition,  highlighting  the  mutation  detected.
recent  genetic  analysis  has  identified  two  genetically  dif-
ferent  forms  of  PHA  1:  Renal  PHA  1  or  AD-PHA  and  Systemic
PHA  1  or  AR-PHA  1.9 Aldosterone,  our  most  potent  miner-
alocorticoid,  plays  an  important  role  in  the  regulation  of
sodium--potassium  balance  and  blood  pressure  through  its
effects  on  the  ENaC.2 This  is done  by  aldosterone  binding  to
intracytoplasmic  MR,  which  then  leads  to  a  signaling  cascade
that  increases  the  activity  of  ENaC.  Disruption  of  this  pro-
cess,  by  mutations  in  either  the  MR  or  ENaC,  leads  to  PHA  1,
an  aldosterone  unresponsiveness  syndrome  and  is  thus  char-
acterized  by  three  essential  features:  (1)  hyperkalemia,  (2)
hyponatremia  and  (3)  metabolic  acidosis,  in  the  presence
of  abnormally  elevated  serum  aldosterone  and  plasma  renin
activity.3 Such  mineralocorticoid  resistance  may  be  isolated
to  the  kidney  (renal  PHA  1  or  AD-PHA  1)  or  may  be  systemic
(systemic  PHA  1  or  AR-PHA  1).  Renal  PHA  1  is  a  rare  autoso-
mal  dominant  form  of  mineralocorticoid  resistance  caused
by  mutations  in  the  NR3C2  gene  that  encodes  the  MR.9 This
mineralocorticoid  unresponsiveness  is  isolated  to  the  kid-
ney  leading  commonly  to  a  mild  to  moderate  loss  of  sodium
that  responds  well  to  sodium  supplementation  and  gener-
ally  improves  spontaneously  with  age,  possibly  because  of  a
maturation  in  the  proximal  reabsorption  of  sodium.2,9 How-
ever,  a  fist  case  of  autosomal  recessive  PHA  1  caused  by
compound  heterozygotous  mutations  in  the  MR  gene  has
been  described  associated  with  a  severe  phenotype.12 Sys-
temic  PHA  1  is  caused  by  loss  of  function  mutations  of
the  ENaC  subunit  genes:  SCNN1A  (chromosome  12p13.31),
SCNN1B  (chromosome  16p12.1)  and  SCNN1G  (chromosome
16p12.1).8 This  form  is  associated  with  autosomal  recessive
transmission.6 ENaC  is  a  hetero-multimeric  protein  formed
by  three  subunits  (alpha,  beta,  and  gamma)  and  is  expressed
in  multiple  tissues:  distal  nephron,  colon,  sweat  and  sali-
vary  glands  and  epithelial  lung  cells.  Therefore,  this  is  a
more  severe  condition  because  of  a  systemic  mineralocorti-
coid  resistance,  with  affected  patients  requiring  extremely
high  doses  of  sodium  to  compensate  their  multiorgan  salt
wasting  and  sometimes  fatal  hyperkalemia.2 Additional
medical  management  consists  on  potassium-lowering  agents
like  ion  exchangers  and  low  potassium  diet.11 Elevated
sodium  concentration  in  sweat  and  absent  nasal  or  rec-
tal  transepithelial  voltage  differences  can  be  used  as  quick
diagnostic  tools.11 Spontaneous  remissions  have  not  been
described  and  patients  require  massive  sodium  supplemen-
tation  throughout  life.  Of  interest,  affected  newborns,  as
like  ours,  also  manifest  a pulmonary  syndrome  characterized
by  recurrent  episodes  of  tachypnea  and  fever,  mimicking
respiratory  infections,  but  without  identifiable  bacterial  air-
way  infection.  This  occurs  probably  due  to  impaired  ability
to  absorb  liquid  from  airway  surfaces.7,8,13 Consistent  with
these  findings,  mice  with  disrupted  alpha  or  beta  subunits
of  ENaC  die  at  birth  from  respiratory  failure  due  to  an
inability  to  reabsorb  lung  water.2 However,  most  of  AR-
PHA  1  patients  do  not  have  neonatal  respiratory  distress
syndromes.11
In  our  case,  it  was  the  severity  of  his  clinical  course  and
his  systemic  manifestations  that  made  the  clinical  diagno-
sis  of  AR-PHA  1  or  systemic  PHA  1,  leading  to  screening  of
ENaC  mutations.  Our  patient  has  a  homozygous  mutation  in
intron  3  of  the  SCNN1A  gene  (c.1052  +  2dupT).  The  major-
ity  of  the  AR-PHA  1  mutations  are  localized  on  the  SCNN1A
gene,  with  mutations  most  frequently  located  on  exon  8.5
The  majority  of  mutations  responsible  for  multisystem  PHA
1  reported  to  date,  are  nonmissense  mutations,  leading  to
absence  of  normal  length  protein  and  are  associated  with
a  severe  phenotype.5,11 Missense  mutations,  lead  to  normal
length  protein,  and  thus  a more  functional  subunit  than  an
absent  one,  and  therefore  these  mutations  are  associated
with  milder  phenotypes.5 The  mutation  described,  albeit
not  previously  described,  is  neither  a  missense,  frameshift,
nor  nonsense  mutation,  but  rather  a splice  site  mutation.
Although  it  has  not  been  described  in  the  literature,  and
therefore  we  do  not  know  the  precise  effect  of  the  mutation
on  the  ENaC  structure  and  function,  its  location  very  closely
to  the  highly  conserved  donor  splice  site  of  intron  3 will
most  probably  affect  the  RNA  splicing  of  this  gene  and  there-
fore  to  a  grossly  abnormal  protein,  and  should  therefore  be
considered  as  most  likely  clinically  relevant.
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Another  extremely  curious  fact  is  that  his  older  sibling
has  Chediak--Higashi  syndrome,  another  rare  genetic  disease
that  has  no  relationship  with  PHA  1.  Genetic  analysis  of  his
parents  is  currently  under  study.
Conclusion
The  PHA  1  phenotype  of  our  patient  was  particularly  severe,
making  normalization  of  electrolytes  a  challenging  task,  only
possible  with  unusually  high  salt  intake  as  well  as  contin-
uous  ion  exchange  resin.  It  remains  uncertain  if  there  is
genotype--phenotype  correlation  due  to  the  rarity  of  the
disease  and  due  to  the  few  reported  patients  with  well
described  clinical  characteristics  and  genotype  available.1,11
However,  it  is  possible  that  different  mutations  correspond
to  different  clinical  phenotypes.5
To  better  understand  the  pathogenesis  of  PAH  1  all  infor-
mation  concerning  an  accurate  description  of  the  clinical
phenotype  and  genotype  should  be  provided  to  the  scientific
community.
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